HepaRegeniX has raised €11 million in Series B funding to advance the first MKK4 inhibitor for the treatment of acute and chronic liver diseases to clinical trial later this year.
The financing round in the Germany company included contributions from all its existing companies including Boehringer Ingelheim Venture Fund and Novo Holdings.
MKK4 (Mitogen-Activated Protein (MAP) Kinase 4) is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
Over the last 2, years, HepaRegeniX focused on discovery of new and proprietary MKK4 inhibitors which led to the identification of several preclinical drug candidates.
Results from experimental, clinically relevant disease models further validated the concept that MKK4-inhibition improves the regeneration capacity of hepatocytes in affected organs and provided strong evidence for successful clinical development.
“This is an exciting phase for HepaRegeniX to soon advance our first compound into the clinic based on compelling preclinical data for our proprietary MKK4 inhibitor,” said Dr. Michael Lutz, CEO of HepaRegeniX.